Covid-19 roundup: Moderna reportedly lacking enough minority participants; Pfizer, BioNTech and Regeneron sued for alleged patent infringement
Private contractors working for Moderna $MRNA did not enroll enough minority participants in its Covid-19 vaccine trial to determine whether or not the candidate works in these populations, according to a Reuters report.
To make up for this discrepancy, Moderna slowed enrollment of the study and directed trial sites to focus on recruiting more Black, Latino and Native American volunteers, company executives told Reuters. Per the report, the contractors quickly filled a large portion of the 30,000-patient trial with mostly white participants despite Covid-19 infecting three times as many Black individuals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.